Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Edmond M. Kwan, Heidi Fettke, Maria M. Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Lisa Jane K. Graham, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhöfer, Lisa G. Horvath, Arun A. Azad

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


We demonstrated that a whole-blood androgen receptor-based multigene signature was an important prognostic tool in a cohort of metastatic castration-resistant prostate cancer (mCRPC)patients receiving contemporaneous systemic treatment. This signature may have a valuable role in upfront risk stratification and prognostication of mCRPC patients.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalEuropean Urology Focus
Issue number1
Publication statusPublished - 1 Jan 2021


  • Androgen receptor
  • Androgen receptor splice variant
  • Biomarker
  • Castration-resistant prostate cancer
  • Chemotherapy
  • Prognosis

Cite this